Intellia Therapeutics Inc
NASDAQ:NTLA

Watchlist Manager
Intellia Therapeutics Inc Logo
Intellia Therapeutics Inc
NASDAQ:NTLA
Watchlist
Price: 8.26 USD 0.61%
Market Cap: 886.7m USD
Section:
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one NTLA stock under the Base Case scenario is 10.14 USD. Compared to the current market price of 8.26 USD, Intellia Therapeutics Inc is Undervalued by 19%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NTLA Relative Value
Base Case
10.14 USD
Undervaluation 19%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

16.5
P/S
P/S
Price to Sales
16.5
vs History
95
vs Industry
35
Median 3Y
29.4
Median 5Y
62.6
Industry
7.6
Forward
15.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-3.3
Median 5Y
-7.7
Industry
23.9
Forward
-2.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-9.3
Industry
20.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.8
Median 5Y
-8.9
Industry
22.4
More Details
1.3
P/B
P/B
Price to Book Value
1.3
vs History
90
vs Industry
59
Median 3Y
2.3
Median 5Y
2.9
Industry
3.1
More Details
7.6
EV/S
EV/S
Enterprise Value to Sales
7.6
vs History
93
vs Industry
52
Median 3Y
21.2
Median 5Y
45.2
Industry
8.2
Forward
7
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-5.7
Industry
6.1
Forward
-1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-5.6
Industry
6.5
Forward
-1
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-6.7
Industry
7.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-4
Median 5Y
-6.4
Industry
5.8
More Details
1.1
EV/IC
EV/IC
Enterprise Value to IC
1.1
vs History
88
vs Industry
64
Median 3Y
3.7
Median 5Y
6
Industry
5.3
More Details

Multiples Across Competitors

NTLA Competitors Multiples
Intellia Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Intellia Therapeutics Inc
NASDAQ:NTLA
950.6m USD 16.5 -2.1 -0.9 -0.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 476 503.8 -163 861.7 -198 980.4 -196 709.8
US
Abbvie Inc
NYSE:ABBV
417.6B USD 7 177.8 17.1 24.3
US
Amgen Inc
NASDAQ:AMGN
181.6B USD 5 25.9 18.6 18.6
US
Gilead Sciences Inc
NASDAQ:GILD
157.3B USD 5.4 19.4 13.1 13.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.4B USD 9.2 29.5 21.6 22.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 043.4 -521.4 -567.8 -552.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD 5.6 17.4 16.6 18.8
AU
CSL Ltd
ASX:CSL
88.6B AUD 3.7 19.1 12.8 16
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
57.2B USD 23.2 -179.1 -447.3 -307
NL
argenx SE
XBRU:ARGX
48.5B EUR 15.5 36.4 63.1 64.8
P/E Multiple
Earnings Growth PEG
US
Intellia Therapeutics Inc
NASDAQ:NTLA
Average P/E: 46.5
Negative Multiple: -2.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 861.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
177.8
89%
2
US
Amgen Inc
NASDAQ:AMGN
25.9
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.4
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
8%
2.2
AU
CSL Ltd
ASX:CSL
19.1
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -179.1 N/A N/A
NL
argenx SE
XBRU:ARGX
36.4
37%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Intellia Therapeutics Inc
NASDAQ:NTLA
Average EV/EBITDA: 23.3
Negative Multiple: -0.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 980.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.6
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.1
7%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -567.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
9%
1.8
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -447.3 N/A N/A
NL
argenx SE
XBRU:ARGX
63.1
769%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Intellia Therapeutics Inc
NASDAQ:NTLA
Average EV/EBIT: 25.4
Negative Multiple: -0.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 709.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.3
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.6
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
13.1
13%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -552.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
12%
1.6
AU
CSL Ltd
ASX:CSL
16
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -307 N/A N/A
NL
argenx SE
XBRU:ARGX
64.8
N/A N/A

See Also

Summary
NTLA intrinsic value, competitors valuation, and company profile.
DCF Valuation
NTLA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NTLA stock valuation using valuation multiples.
Wall Street Estimates
NTLA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NTLA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 298,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.